<DOC>
	<DOC>NCT01119924</DOC>
	<brief_summary>The purpose of this study is to evaluate the Efficacy and Safety of Smilon® in the Depression Patients with pain. Eligible patients will be randomly assigned to 1 of 2 arms, either Smilon® or placebo, and will receive the treatment for 8 weeks in this study.</brief_summary>
	<brief_title>A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Male or female Age 2065 years Diagnosis of at least one chronic pain syndrome and the diagnosis of concomitant depression according to DSMIV criteria Have a mean weekly pain score of at least 30 mm on the 100mm visual analog scale (VAS) of the ShortForm McGill Pain Questionnaire (SFMPQ) before study entry Women of child bearing potential who are pregnant, breastfeeding or not using effective contraceptives Known hypersensitivity to Mirtazapine or any of its components Subjects who have a clinically significant or unstable medical or psychiatric condition Subjects who have received nerve blocks or acupuncture for pain relief</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Mirtazapine</keyword>
	<keyword>Smilon</keyword>
	<keyword>Depression</keyword>
	<keyword>Pain</keyword>
</DOC>